{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:25:46Z","timestamp":1787761546142,"version":"build-2784847793"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20dm0107119"],"award-info":[{"award-number":["JP20dm0107119"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H02846"],"award-info":[{"award-number":["21H02846"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772044"],"award-info":[{"award-number":["81772044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    (\n                    <jats:italic>R, S<\/jats:italic>\n                    )-ketamine has prophylactic antidepressant-like effects in rodents; however, the precise molecular mechanisms underlying its action remain unknown. Using RNA-sequencing analysis, we searched novel molecular target(s) that contribute to the prophylactic effects of (\n                    <jats:italic>R<\/jats:italic>\n                    )-ketamine, a more potent enantiomer of (\n                    <jats:italic>R, S<\/jats:italic>\n                    )-ketamine. Pretreatment with (\n                    <jats:italic>R<\/jats:italic>\n                    )-ketamine (10 mg\/kg, 6 days before) significantly ameliorated body weight loss, splenomegaly, and increased immobility time of forced swimming test in lipopolysaccharide (LPS: 1.0 mg\/kg)-treated mice. RNA-sequencing analysis of prefrontal cortex (PFC) and subsequent IPA (Ingenuity Pathway Analysis) revealed that the nuclear factor of activated T cells 4 (NFATc4) signaling might contribute to sustained prophylactic effects of (\n                    <jats:italic>R<\/jats:italic>\n                    )-ketamine. Quantitative RT-PCR confirmed that (\n                    <jats:italic>R<\/jats:italic>\n                    )-ketamine significantly attenuated the increased gene expression of NFATc4 signaling (\n                    <jats:italic>Nfatc4, Cd4, Cd79b, H2-ab1<\/jats:italic>\n                    ,\n                    <jats:italic>H2-aa<\/jats:italic>\n                    ) in the PFC of LPS-treated mice. Furthermore, pretreatment with NFAT inhibitors (i.e., NFAT inhibitor and cyclosporin A) showed prophylactic effects in the LPS-treated mice. Similar to (\n                    <jats:italic>R<\/jats:italic>\n                    )-ketamine, gene knockdown of\n                    <jats:italic>Nfatc4<\/jats:italic>\n                    gene by bilateral injection of adeno-associated virus (AAV) into the mPFC could elicit prophylactic effects in the LPS-treated mice. In conclusion, our data implicate a novel NFATc4 signaling pathway in the PFC underlying the prophylactic effects of (\n                    <jats:italic>R<\/jats:italic>\n                    )-ketamine for inflammation-related depression.\n                  <\/jats:p>","DOI":"10.1038\/s41398-022-01803-6","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T02:02:53Z","timestamp":1642730573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Nuclear factor of activated T cells 4 in the prefrontal cortex is required for prophylactic actions of (R)-ketamine"],"prefix":"10.1038","volume":"12","author":[{"given":"Li","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youge","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajing","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Ishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-0439","authenticated-orcid":false,"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"1803_CR1","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","volume":"101","author":"JH Krystal","year":"2019","unstructured":"Krystal JH, Abdallah CG, Sanacora G, Charney D, Duman RS. Ketamine: a paradigm shift for depression research and treatment. Neuron. 2019;101:774\u20138.","journal-title":"Neuron"},{"key":"1803_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351\u20134.","journal-title":"Biol Psychiatry"},{"key":"1803_CR3","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856\u201364.","journal-title":"Arch Gen Psychiatry"},{"key":"1803_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","volume":"67","author":"N Diazgranados","year":"2010","unstructured":"Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793\u2013802.","journal-title":"Arch Gen Psychiatry"},{"key":"1803_CR5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","volume":"71","author":"CA Zarate Jr","year":"2012","unstructured":"Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939\u201346.","journal-title":"Biol Psychiatry"},{"key":"1803_CR6","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","volume":"170","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170:1134\u201342.","journal-title":"Am J Psychiatry"},{"key":"1803_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","volume":"173","author":"JB Singh","year":"2016","unstructured":"Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173:816\u201326.","journal-title":"Am J Psychiatry"},{"key":"1803_CR8","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/npp.2017.94","volume":"42","author":"TP Su","year":"2017","unstructured":"Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, et al. Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017;42:2482\u201392.","journal-title":"Neuropsychopharmacology"},{"key":"1803_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","volume":"176","author":"JL Phillips","year":"2019","unstructured":"Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry. 2019;176:401\u20139.","journal-title":"Am J Psychiatry"},{"key":"1803_CR10","doi-asserted-by":"crossref","unstructured":"Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020;25:1592\u2013603.","DOI":"10.1038\/s41380-018-0256-5"},{"key":"1803_CR11","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","volume":"172","author":"DJ Newport","year":"2015","unstructured":"Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB. APA Council of Research Task Force on Novel Biomarkers and Treatments. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015;172:950\u201366.","journal-title":"Am J Psychiatry"},{"key":"1803_CR12","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1017\/S0033291716000064","volume":"46","author":"T Kishimoto","year":"2016","unstructured":"Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, et al. Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety, and time trajectories. Psychol Med. 2016;46:1459\u201372.","journal-title":"Psychol Med"},{"key":"1803_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","volume":"106","author":"W Zheng","year":"2018","unstructured":"Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, et al. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. Psychiatry Res. 2018;106:61\u20138.","journal-title":"Psychiatry Res"},{"key":"1803_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrd.2017.16","volume":"16","author":"JW Murrough","year":"2017","unstructured":"Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signaling in depression: progress and prospects. Nat Rev Drug Discov. 2017;16:472\u201386.","journal-title":"Nat Rev Drug Discov"},{"key":"1803_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev-pharmtox-010617-052811","volume":"59","author":"TD Gould","year":"2019","unstructured":"Gould TD, Zarate CA Jr, Thompson SM. Molecular pharmacology and neurobiology of rapid-acting antidepressants. Annu Rev Pharmacol Toxicol. 2019;59:213\u201336.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1803_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/pcn.12902","volume":"73","author":"K Hashimoto","year":"2019","unstructured":"Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci. 2019;73:613\u201327.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1803_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0624-1","volume":"9","author":"C Yang","year":"2019","unstructured":"Yang C, Yang J, Luo A, Hashimoto K. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Transl Psychiatry. 2019;9:280.","journal-title":"Transl Psychiatry"},{"key":"1803_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/14737175.2019.1554434","volume":"19","author":"K Zhang","year":"2019","unstructured":"Zhang K, Hashimoto K. An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Rev Neurother. 2019;19:83\u201392.","journal-title":"Expert Rev Neurother"},{"key":"1803_CR19","doi-asserted-by":"publisher","first-page":"113935","DOI":"10.1016\/j.bcp.2020.113935","volume":"177","author":"K Hashimoto","year":"2020","unstructured":"Hashimoto K. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem Pharmacol. 2020;177:113935.","journal-title":"Biochem Pharmacol"},{"key":"1803_CR20","doi-asserted-by":"publisher","first-page":"172870","DOI":"10.1016\/j.pbb.2020.172870","volume":"190","author":"Y Wei","year":"2020","unstructured":"Wei Y, Chang L, Hashimoto K. A historical review of antidepressant effects of ketamine and its enantiomers. Pharmacol Biochem Behav. 2020;190:172870.","journal-title":"Pharmacol Biochem Behav"},{"key":"1803_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.biopsych.2021.05.008","volume":"90","author":"E Castren","year":"2021","unstructured":"Castren E, Monteggia LM. Brain-derived neurotrophic factor signaling in depression and antidepressant action. Biol Psychiatry. 2021;90:128\u201336.","journal-title":"Biol Psychiatry"},{"key":"1803_CR22","doi-asserted-by":"publisher","unstructured":"Wei Y, Chang L, Hashimoto K, Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Mol Psychiatry. 2021. https:\/\/doi.org\/10.1038\/s41380-021-01121-1.","DOI":"10.1038\/s41380-021-01121-1"},{"key":"1803_CR23","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.biopsych.2015.04.022","volume":"79","author":"RA Brachman","year":"2016","unstructured":"Brachman RA, McGowan JC, Perusini JN, Lim SC, Pham TH, Faye C, et al. Ketamine as a prophylactic against stress-induced depressive-like behavior. Biol Psychiatry. 2016;79:776\u201386.","journal-title":"Biol Psychiatry"},{"key":"1803_CR24","doi-asserted-by":"publisher","first-page":"112238","DOI":"10.1016\/j.bbr.2019.112238","volume":"378","author":"A Mastrodonato","year":"2020","unstructured":"Mastrodonato A, Cohensedgh O, LaGamma CT, McGowan JC, Hunsberger HC, Denny CA. Prophylactic (R,S)-ketamine selectively protects against inflammatory stressors. Behav Brain Res. 2020;378:112238.","journal-title":"Behav Brain Res"},{"key":"1803_CR25","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/npp.2017.19","volume":"42","author":"JC McGowan","year":"2017","unstructured":"McGowan JC, LaGamma CT, Lim SC, Tsitsiklis M, Neria Y, Brachman RA, et al. Prophylactic ketamine attenuates learned fear. Neuropsychopharmacology. 2017;42:1577\u201389.","journal-title":"Neuropsychopharmacology"},{"key":"1803_CR26","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41386-018-0043-7","volume":"43","author":"JC McGowan","year":"2018","unstructured":"McGowan JC, Hill C, Mastrodonato A, LaGamma CT, Kitayev A, Brachman RA, et al. Prophylactic ketamine alters nucleotide and neurotransmitter metabolism in brain and plasma following stress. Neuropsychopharmacology. 2018;43:1813\u201321.","journal-title":"Neuropsychopharmacology"},{"key":"1803_CR27","doi-asserted-by":"crossref","unstructured":"Mastrodonato A, Martinez R, Pavlova IP, LaGamma CT, Brachman RA, Robison AJ, et al. Ventral CA3 activation mediates prophylactic ketamine efficacy against stress-induced depressive-like behavior. Biol Psychiatry. 2018;84:846\u201356.","DOI":"10.1016\/j.biopsych.2018.02.011"},{"key":"1803_CR28","doi-asserted-by":"crossref","unstructured":"Parise EM, Parise LF, Sial OK, Cardona-Acosta AM, Gyles TM, Juarez B, et al. The resilient phenotype induced by prophylactic ketamine exposure during adolescence is mediated by the ventral tegmental area\u2013nucleus accumbens pathway. Biol Psychiatry. 2021;90:482\u201393.","DOI":"10.1016\/j.biopsych.2021.05.002"},{"key":"1803_CR29","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.psychres.2019.03.026","volume":"279","author":"JH Ma","year":"2019","unstructured":"Ma JH, Wang SY, Yu HY, Li DY, Luo SC, Zheng SS, et al. Prophylactic use of ketamine reduces postpartum depression in Chinese women undergoing cesarean section. Psychiatry Res. 2019;279:252\u20138.","journal-title":"Psychiatry Res"},{"key":"1803_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/bs.apha.2020.05.004","volume":"89","author":"A Feder","year":"2020","unstructured":"Feder A, Rutter SB, Schiller D, Charney DS. The emergence of ketamine as a novel treatment for posttraumatic stress disorder. Adv Pharm. 2020;89:261\u201386.","journal-title":"Adv Pharm"},{"key":"1803_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","volume":"116","author":"JC Zhang","year":"2014","unstructured":"Zhang JC, Li SX, Hashimoto K. R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochem Behav. 2014;116:137\u201341.","journal-title":"Pharmacol Biochem Behav"},{"key":"1803_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.136","volume":"5","author":"C Yang","year":"2015","unstructured":"Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632.","journal-title":"Transl Psychiatry"},{"key":"1803_CR33","doi-asserted-by":"crossref","unstructured":"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481\u20136.","DOI":"10.1038\/nature17998"},{"key":"1803_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1124\/jpet.116.239228","volume":"361","author":"K Fukumoto","year":"2017","unstructured":"Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi JI, Hashimoto K, et al. Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther. 2017;361:9\u201316.","journal-title":"J Pharmacol Exp Ther"},{"key":"1803_CR35","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.biopsych.2016.12.020","volume":"82","author":"C Yang","year":"2017","unstructured":"Yang C, Qu Y, Abe M, Nozawa D, Chaki S, Hashimoto K. (R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine. Biol Psychiatry. 2017;82:e43\u2013e44.","journal-title":"Biol Psychiatry"},{"key":"1803_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-017-0031-4","volume":"7","author":"C Yang","year":"2017","unstructured":"Yang C, Qu Y, Fujita Y, Ren Q, Ma M, Dong C, et al. Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model. Transl Psychiatry. 2017;7:1294.","journal-title":"Transl Psychiatry"},{"key":"1803_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","volume":"83","author":"C Yang","year":"2018","unstructured":"Yang C, Ren Q, Qu Y, Zhang JC, Ma M, Dong C, et al. Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry. 2018;83:18\u201328.","journal-title":"Biol Psychiatry"},{"key":"1803_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","volume":"181","author":"L Chang","year":"2019","unstructured":"Chang L, Zhang K, Pu Y, Qu Y, Wang SM, Xiong Z, et al. Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacol Biochem Behav. 2019;181:53\u20139.","journal-title":"Pharmacol Biochem Behav"},{"key":"1803_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0733-x","volume":"10","author":"K Zhang","year":"2020","unstructured":"Zhang K, Yang C, Chang L, Sakamoto A, Suzuki T, Fujita Y, et al. Essential role of microglial transforming growth factor-\u03b21 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-\u03b21. Transl Psychiatry. 2020;10:32.","journal-title":"Transl Psychiatry"},{"key":"1803_CR40","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.3390\/ijerph17134710","volume":"17","author":"J Zhu","year":"2020","unstructured":"Zhu J, Hawkins E, Phillips K, Deshpande LS. Assessment of ketamine and its enantiomers in an organophosphate-based rat model for features of Gulf War illness. Int J Environ Res Public Health. 2020;17:4710.","journal-title":"Int J Environ Res Public Health"},{"key":"1803_CR41","doi-asserted-by":"crossref","unstructured":"Rafa\u0142o-Uli\u0144ska A, Pa\u0142ucha-Poniewiera A. The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL\/6J mice. Behav Brain Res. 2022;418:113633.","DOI":"10.1016\/j.bbr.2021.113633"},{"key":"1803_CR42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.psychres.2016.03.034","volume":"239","author":"C Yang","year":"2016","unstructured":"Yang C, Han M, Zhang JC, Ren Q, Hashimoto K. Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res. 2016;239:281\u20133.","journal-title":"Psychiatry Res"},{"key":"1803_CR43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00406-016-0692-7","volume":"267","author":"K Hashimoto","year":"2017","unstructured":"Hashimoto K, Kakiuchi T, Ohba H, Nishiyama S, Tsukada H. Reduction of dopamine D2\/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci. 2017;267:173\u20136.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1803_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pbb.2018.07.003","volume":"172","author":"Z Tian","year":"2018","unstructured":"Tian Z, Dong C, Fujita A, Fujita Y, Hashimoto K. Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine. Pharmacol Biochem Behav. 2018;172:17\u201321.","journal-title":"Pharmacol Biochem Behav"},{"key":"1803_CR45","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and ketamine metabolites pharmacology: Insights into therapeutic mechanisms. Pharmacol Rev. 2018;70:621\u201360.","journal-title":"Pharmacol Rev"},{"key":"1803_CR46","doi-asserted-by":"publisher","unstructured":"Bonaventura J, Lam S, Carlton M, Boehm MA, Gomez JL, Sol\u00eds O, et al., Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol. Psychiatry. 2021 Apr. https:\/\/doi.org\/10.1038\/s41380-021-01093-2.","DOI":"10.1038\/s41380-021-01093-2."},{"key":"1803_CR47","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","volume":"271","author":"GC Leal","year":"2021","unstructured":"Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, et al. Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci. 2021;271:577\u201382.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1803_CR48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1126\/science.1222939","volume":"338","author":"RS Duman","year":"2012","unstructured":"Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338:68\u201372.","journal-title":"Science"},{"key":"1803_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00406-016-0718-1","volume":"267","author":"Y Shirayama","year":"2017","unstructured":"Shirayama Y, Hashimoto K. Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. Eur Arch Psychiatry Clin Neurosci. 2017;267:177\u201382.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1803_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00878-3","volume":"10","author":"J Zhang","year":"2020","unstructured":"Zhang J, Ma L, Chang L, Pu Y, Qu Y, Hashimoto K. A key role of the subdiaphragmatic vagus nerve in the depression-like phenotype and abnormal composition of gut microbiota in mice after lipopolysaccharide administration. Transl Psychiatry. 2020;10:186.","journal-title":"Transl Psychiatry"},{"key":"1803_CR51","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.biopsych.2018.05.007","volume":"84","author":"C Yang","year":"2018","unstructured":"Yang C, Kobayashi S, Nakao K, Dong C, Han M, Qu Y, et al. AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-norketamine. Biol Psychiatry. 2018;84:591\u2013600.","journal-title":"Biol Psychiatry"},{"key":"1803_CR52","doi-asserted-by":"publisher","first-page":"E1499","DOI":"10.1073\/pnas.1202068109","volume":"109","author":"G Quadrato","year":"2012","unstructured":"Quadrato G, Benevento M, Alber S, Jacob C, Floriddia EM, Nguyen T, et al. Nuclear factor of activated T cells (NFATc4) is required for BDNF-dependent survival of adult-born neurons and spatial memory formation in the hippocampus. Proc Natl Acad Sci USA. 2012;109:E1499\u2013508.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1803_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00213-019-05346-5","volume":"237","author":"A Fujita","year":"2020","unstructured":"Fujita A, Fujita Y, Pu Y, Chang L, Hashimoto K. MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling. Psychopharmacology. 2020;237:83\u201392.","journal-title":"Psychopharmacology"},{"key":"1803_CR54","doi-asserted-by":"publisher","first-page":"172839","DOI":"10.1016\/j.pbb.2019.172839","volume":"188","author":"Y Tan","year":"2020","unstructured":"Tan Y, Fujita Y, Qu Y, Chang L, Pu Y, Wang S, et al. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: Role of BDNF-TrkB signaling. Pharmacol Biochem Behav. 2020;188:172839.","journal-title":"Pharmacol Biochem Behav"},{"key":"1803_CR55","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00406-020-01208-w","volume":"271","author":"Y Qu","year":"2021","unstructured":"Qu Y, Shan J, Wang S, Chang L, Pu Y, Wang X, et al. Rapid-acting and long-lasting antidepressant-like actions of (R)-ketamine in Nrf2 knock-out mice: a role of TrkB signaling. Eur Arch Psychiatry Clin Neurosci. 2021;271:439\u201346.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1803_CR56","doi-asserted-by":"publisher","first-page":"173954","DOI":"10.1016\/j.ejphar.2021.173954","volume":"897","author":"Y Fujita","year":"2021","unstructured":"Fujita Y, Hashimoto Y, Hashimoto H, Chang L, Hashimoto K. Dextran sulfate sodium-induced inflammation and colitis in mice are ameliorated by (R)-ketamine, but not (S)-ketamine: A role of TrkB signaling. Eur J Pharmacol. 2021;897:173954.","journal-title":"Eur J Pharmacol"},{"key":"1803_CR57","first-page":"pyu077","volume":"18","author":"JC Zhang","year":"2014","unstructured":"Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C, et al. Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharmacol. 2014;18:pyu077.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1803_CR58","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00213-016-4483-7","volume":"234","author":"M Ma","year":"2017","unstructured":"Ma M, Ren Q, Yang C, Zhang JC, Yao W, Dong C, et al. Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation. Psychopharmacology. 2017;234:525\u201333.","journal-title":"Psychopharmacology"},{"key":"1803_CR59","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kr\u00e4mer","year":"2014","unstructured":"Kr\u00e4mer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014;30:523\u201330.","journal-title":"Bioinformatics"},{"key":"1803_CR60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.neulet.2016.07.020","volume":"630","author":"K Kobayashi","year":"2016","unstructured":"Kobayashi K, Sano H, Kato S, Kuroda K, Nakamuta S, Isa T, et al. Survival of corticostriatal neurons by Rho\/Rho-kinase signaling pathway. Neurosci Lett. 2016;630:45\u201352.","journal-title":"Neurosci Lett"},{"key":"1803_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07325-2","volume":"7","author":"JC Zhang","year":"2017","unstructured":"Zhang JC, Yao W, Qu Y, Nakamura M, Dong C, Yang C, et al. Increased EphA4\u2013ephexin1 signaling in the medial prefrontal cortex plays a role in depression-like phenotype. Sci Rep. 2017;7:7133.","journal-title":"Sci Rep"},{"key":"1803_CR62","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/ijnp\/pyx108","volume":"21","author":"Y Shirayama","year":"2018","unstructured":"Shirayama Y, Hashimoto K. Lack of antidepressant effects of (2R,6R)-hydroxynorketamine in a rat learned helplessness model: comparison with (R)-ketamine. Int J Neuropsychopharmacol. 2018;21:84\u20138.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1803_CR63","doi-asserted-by":"crossref","unstructured":"Zhang J, Ma L, Wan X, Shan J, Qu Y, Hashimoto K. (R)-Ketamine attenuates LPS-induced endotoxin-derived delirium through inhibition of neuroinflammation. Psychopharmacology. 2021;238:2743\u201353.","DOI":"10.1007\/s00213-021-05889-6"},{"key":"1803_CR64","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s10571-013-9955-2","volume":"33","author":"L Li","year":"2013","unstructured":"Li L, Ke K, Tan X, Xu W, Shen J, Zhai T, et al. Up-regulation of NFATc4 involves in neuronal apoptosis following intracerebral hemorrhage. Cell Mol Neurobiol 2013;33:893\u2013905.","journal-title":"Cell Mol Neurobiol"},{"key":"1803_CR65","doi-asserted-by":"publisher","first-page":"8125","DOI":"10.1523\/JNEUROSCI.23-22-08125.2003","volume":"23","author":"RD Groth","year":"2003","unstructured":"Groth RD, Mermelstein PG. Brain-derived neurotrophic factor activation of NFAT (nuclear factor of activated T-cells)-dependent transcription: a role for the transcription factor NFATc4 in neurotrophin-mediated gene expression. J Neurosci. 2003;23:8125\u201334.","journal-title":"J Neurosci"},{"key":"1803_CR66","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1146\/annurev.immunol.15.1.707","volume":"15","author":"A Rao","year":"1997","unstructured":"Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Ann Rev Immunol. 1997;15:707\u201347.","journal-title":"Ann Rev Immunol"},{"key":"1803_CR67","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nri2818","volume":"10","author":"MR M\u00fcller","year":"2010","unstructured":"M\u00fcller MR, Rao A. NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol. 2010;10:645\u201356.","journal-title":"Nat Rev Immunol"},{"key":"1803_CR68","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00406-019-01092-z","volume":"271","author":"K Zhang","year":"2021","unstructured":"Zhang K, Sakamoto A, Chang L, Qu Y, Wang S, Pu Y, et al. Splenic NKG2D confers resilience versus susceptibility in mice after chronic social defeat stress: beneficial effects of (R)-ketamine. Eur Arch Psychiatry Clin Neurosci. 2021;271:447\u201356.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1803_CR69","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.cpr.2007.02.005","volume":"27","author":"SL Burcusa","year":"2007","unstructured":"Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007;27:959\u201385.","journal-title":"Clin Psychol Rev"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01803-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01803-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01803-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T14:32:42Z","timestamp":1669213962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01803-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1803"],"URL":"https:\/\/doi.org\/10.1038\/s41398-022-01803-6","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KH is the inventor of filed patent applications on \u201cThe use of <i>R<\/i>-Ketamine in the treatment of psychiatric diseases\u201d, \u201c(<i>S<\/i>)-norketamine and salt thereof as pharmaceutical\u201d, \u201c<i>R<\/i>-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder\u201d, \u201cPreventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases\u201d, and \u201c<i>R<\/i>-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder\u201d by the Chiba University. KH has also received speakers\u2019 honoraria, consultant fee, or research support from Abbott, Meiji Seika Pharma, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm, and Perception Neuroscience. Other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}